Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

February 9, 2018: By Jon Swedien

Second SightSecond Sight announced Feb. 5 that surgeons implanted 30 Argus II Retinal Prosthesis Systems worldwide in Q4-2017.

The total sets a quarterly record and is a more than three-fold increase over the seven Argus II systems implanted in Q4-2016.

For the full year, Second Sight reported 75 Argus II implantations, a 79 percent increase over 42 implantations in 2016.

The Argus II converts images captured by a miniature video camera mounted on a patient’s glasses into a series of small electrical pulses. It is designed to induce visual perception in individuals with severe to profound retinitis pigmentosa.

The Argus II had a Medicare reimbursement rate of $150 thousand in 2017, a sharp increase from $95 thousand in 2016.

The 2018 rate is $122,500.

Orion’s First Human Patient

The company also reported Feb. 5 that Nader Pouratian, MD, PhD, implanted the first human patient with the Orion Cortical Visual Prosthesis System.

The Orion works similarly to the Argus II, though it is implanted on the surface of the visual cortex.

Second Sight said a cortical prosthesis system, which bypasses the retina and optic nerve and directly stimulates the visual cortex, has the potential to restore useful vision to patients blinded due to many reasons, including glaucoma, diabetic retinopathy, or forms of cancer and trauma.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

China’s Innovent Plans $500 Million IPO on Hong Kong Exchange

FDA Accepts Bausch + Lomb’s NDA Filing for Loteprednol Etabonate Ophthalmic Gel

Allergan Launches Refresh Repair Lubricant Eye Drops

US Federal Trade Commission Approves Takeda’s Bid for Shire

Nikon to Acquire Ophthalmic Distributor Chuo Sangio to Merge with Optos Subsidiary

Wills Eye Hospital to Use $5 Million Gift to Support Expansion

Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

Iuvo BioScience Acquires Oculos Clinical Research

Alcon Will Be Worth $20 Billion to $30 Billion After Spinoff, Novartis Chairman Says

Katena Acquires Blink Medical, Adding to String of Recent Purchases

Opthea’s Phase IIb Trial for Wet AMD Candidate Reaches Midway Point for Enrollment

Ocugen Starts Phase III Trial of OCU300 for Ocular Graft Versus Host Disease

Oculocare Medical Receives US FDA 510(k) Approval for ALLEYE, an Amsler Grid App

Santen Ventures Invests $1 Million in Qura’s QSmart System

Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

Eyedaptic Presents Augmented Reality Glasses for AMD at OCTANe Summit

Quantel Medical Launches Vitra 2 Photocoagulator

Novartis Announces Plans to Spin Off Alcon

Glaukos Announces FDA Approval of iStent Inject for Lowering IOP

Aerpio Prices $45M Public Offering, Moves to Nasdaq Capital Market

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023